Status:

COMPLETED

Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines

Lead Sponsor:

Novartis Vaccines

Conditions:

Influenza

Eligibility:

All Genders

18-39 years

Phase:

PHASE1

Brief Summary

This trial is designed to evaluate safety, tolerability and immunogenicity of a bedside mixing formulation of adjuvanted influenza vaccines.

Eligibility Criteria

Inclusion

  • Healthy 18 to 39 year old males and females who are in good health and have provided informed consent prior to enrollment

Exclusion

  • serious medical conditions
  • allergies to vaccine components, including but not limited to egg/chicken products
  • reduced immune function
  • recent use of immunosuppressive therapy
  • recent use of influenza vaccine

Key Trial Info

Start Date :

June 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2008

Estimated Enrollment :

72 Patients enrolled

Trial Details

Trial ID

NCT00735020

Start Date

June 1 2008

End Date

August 1 2008

Last Update

January 24 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

I.P.A.S.

Ligornetto, Switzerland, 36 6853

Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines | DecenTrialz